In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GlaxoSmithKline acquires Sanofi-Synthelabo's antithrombotics

Executive Summary

GlaxoSmithKline PLC has acquired the global rights to Sanofi-Synthelabo's injectable antithrombotics Arixtra (fondaparinux sodium) and Fraxiparine (nadroparine calcium) for €453mm ($547mm) in cash up front.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Product Purchase

Related Companies